Date:5/4/2011

of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is the only injectable product approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter painkillers. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma, or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted fluid overload can occur, potentially resulting in hyponatremia, seizure, and death.  For full prescribing information, visit www.acetadote.net.

About KristaloseKristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.

Forward-Looking StatementsThis pr
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Cumberland Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 4, 2011
2. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
3. Cumberland Pharmaceuticals Appoints Rick S. Greene as Vice President, Finance & Accounting
4. Cumberland Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
5. Cumberland Pharmaceuticals Appoints Tan Cheow Choon as Director of International Business
6. Cumberland Pharmaceuticals to Announce 2010 Financial Results on March 8, 2011
7. Cumberland Pharmaceuticals Receives FDA Approval for New Formulation of Acetadote
8. Cumberland Pharmaceuticals Announces Joey Jacobs Has Joined Its Board of Directors
9. Cumberland Pharmaceuticals Announces Voluntary Recall of Acetadote® Vials
10. Cumberland Pharmaceuticals Reports Third Quarter 2010 Financial Results
11. Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010